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cense.Abstract Background: Sentinel Lymph Node Biopsy (SLNB) procedure was found to be an accu-
rate method of staging the axilla in patients with early stage breast cancer. The standard of care for
breast cancer patients with positive SLN metastasis includes complete Axillary Lymph Node
Dissection (ALND). However, in 40–70% of patients, the SLN is the only involved axillary node.
Factors predicting non SLN metastasis should be identiﬁed in order to deﬁne subgroups of patients
with positive SLN in whom the axilla may be staged by SLNB alone.
Objectives: To identify the factors predicting metastatic involvement of the non-SLNs in breast
cancer patients having SLN metastasis.l Breast Cancer Conference,
A. Abbas).
Institute, Cairo University.
.
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24 H. Eldweny et al.Patients and Methods: Data were collected and analyzed from 80 patients with early stage invasive
breast cancer (T1, T2, N0, M0) who underwent SLNB at the Surgical Oncology Department,
Kuwait Cancer Control Center (KCCC) between November 2004 and February 2009. SLNB was
performed using a combined technique (radioactive colloid, and blue dye) in the majority of cases.
In some cases, only one technique was used. Complete ALND was performed in the case of failure
of SLN identiﬁcation and in patients with positive SLN. Multiple variables (patient, tumor, and
SLN characteristics) were tested as possible predictors of nonsentinel lymph node metastasis.
Results: The mean age of patients at diagnosis was 46.6 years. The median tumor size was 2 cm. The
SLN identiﬁcation rate was 96.2% (77 out of 80 patients). The SLN was positive in 24 patients
(31%), and half of these showed evidence of capsular invasion. The median number of SLNs
removed was two. The median number of positive SLNs was one. The incidence of non-SLN metas-
tasis associated with positive SLN was 50% (12 out of 24 patients). Lymphovascular invasion was
found to be the only factor associated with non-SLN metastases. In addition, two trends were
observed, though they did not reach the statistical signiﬁcance: the ﬁrst is that the majority of
patients having capsular invasion of the SLN (8 out of 12 patients, 67%) had positive non-SLN
metastasis, and the second is that the patients having more than one SLN metastasis were more
likely to have non-SLN metastasis (4 out of 5, 80%).
Conclusion: In the current pilot study, only the lymphovascular invasion in the area of the primary
tumor was found to be signiﬁcantly related to the nonsentinel lymph node metastasis. There was a
tendency toward higher incidence of nonsentinel lymph node metastasis associated with the number
of positive SLN and capsular invasion of SLN, though this did not reach the statistical signiﬁcance.
This could be attributed to the small number of patients recruited. Further evaluation of the pre-
dictors of nonsentinel lymph node metastasis on a larger number of patients is required. The val-
idation of these predictors in prospective studies may enable approximately half of early stage
breast cancer patients with positive SLN to be staged with SLNB alone while avoiding the morbid-
ity of unnecessary ALND.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Surgical intervention in the diagnosis and treatment of breast
cancer has undergone an extensive transformation from radi-
cal mastectomy to lumpectomy, lymph node dissection, and
irradiation in appropriately selected patients. The trend
toward conservative surgical intervention without compromis-
ing cure is also being applied to the evaluation of the axillary
lymph nodes [1].
Sentinel Lymph Node Biopsy (SLNB), introduced by Krag
et al. [2] and Giuliano et al. [3] in the early 1990s, represents a
new standard of care for axillary node staging in patients with
early-stage, clinically node-negative breast cancer. SLN is the
ﬁrst lymph node in a nodal basin to drain the primary tumor
[3]. In theory, if the Sentinel Lymph Node (SLN) does not con-
tain metastatic cancer, the remainder of the nodal basin will be
negative for metastasis. Therefore, the morbidity of nodal dis-
section can be avoided in patients with negative SLN [4]. In
breast cancer, multiple studies have shown that the SLN is
accurate in predicting the absence of nodal metastasis [5–7].
If histopathologic examination shows that the SLN is free of
metastasis, the other nodes in the same axilla are highly unli-
kely (1–2%) to contain tumor cells and the patient is unlikely
to beneﬁt from ALND [8]. The false negative rate of SLNB,
which is the proportion of patients with negative SLNs but
with subsequently proven axillary metastases, has varied be-
tween 0% and 20% of all node positive patients [9].
If a positive SLN is found, it is currently recommended to
continue with ALND [10]. However, in 40–70% of patients the
SLN is the only involved axillary node [1,11–13], implying thatthese patients are undergoing unnecessary ALND, with no ther-
apeutic beneﬁt or further staging information provided [14].
Factors predicting nonSentinel Lymph Node (non-SLN)
metastasis should be identiﬁed in order to deﬁne the subgroup
of patients with positive SLN in whom the axilla may be staged
by SLN biopsy alone [15].
The aim of the current study is to identify the factors
predicting metastatic involvement of the non-SLNs in breast
cancer patients having SLN metastasis.
Patients and methods
The data of the patients having early stage invasive breast can-
cer (T1, T2, N0 and M0) who underwent SLN biopsy at the
Surgical Oncology Department of the Kuwait Cancer Control
Center (KCCC) between November 2004 and February 2009
were collected and analyzed.
Inclusion criteria
Early stage invasive breast cancer with clinically negative axil-
lary lymph nodes. (T1/T2, N0 and M0), histologic or cytologic
diagnosis of the primary tumor obtained, successful SLNB in
which at least one SLN is identiﬁed, metastatic disease is iden-
tiﬁed in the SLN and complete ALND was performed .
Deﬁnitions
A node was considered to be a SLN if it was identiﬁed by 1 or
more of the following three criteria [1]: (1) the node was blue;
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leading to it; (3) the node had an in vivo radioactivity at least
three times the background count.
The non-SLNs were deﬁned as all the non-stained and/or
the non-radioactive lymph nodes removed either during the
SLNB procedure (i.e., palpable nodes) or during the ALND
[16].
SLNB technique
SLNB was performed using one of the following techniques,
which were previously described: preoperative lymphoscintig-
raphy with radioactive nanocolloid alone [5], blue dye tech-
nique alone [3], or combined technique using radioactive
colloid and blue dye [17].
Preoperative lymphoscintigraphy
Lymphoscintigraphy was performed in the day of surgery and
we adopted the technique previously reported by Veronesi
et al. [18]. Technetium-99 (1 mCi) labeled nanocolloid was
divided in four aliquots of 0.4 ml in tuberculin syringes. These
were injected intradermally in the area of the skin overlying the
tumor. Patients were imaged using dual head gamma camera.
Dynamic images (128 · 128 matrix) of 1 min per hour for
30 min were obtained in anterior projection followed by static
anterior and lateral images of the breast and axilla. Gamma
ﬁnder probe was used to localize the SLN on the skin in the
camera room, preoperatively in the theater, and after surgical
excision of the SLN.
Surgical technique
Surgery was performed 2–3 h after lymphoscintigraphy. After
induction of general anesthesia, 2–3 ml of patent blue dye was
injected in different locations, according to the operating sur-
geon: (1) Peritumoral; (2) Periareolar; or (3) in the area of the
skin overlying the tumor. In the latter two locations, the dye
was injected either intradermally or subcutaneously. If an exci-
sion biopsy had been previously performed, the dye was
injected at the periphery of the wall of the biopsy cavity. The
breast was then massaged for 5–10 min. A hand held gamma
probe was used to identify the areas of increased radioactivity
in the axilla and skin markings were drawn over these areas. A
small transverse axillary incision was then made at the axillary
hair line and the axillary fascia divided. Blue stained lymphatic
channel was followed to the blue stained lymph nodes which
were then dissected. The gamma probe was used to identify
the radioactive (hot) nodes. All blue stained and/or radioactive
nodes were removed and labeled ‘‘Sentinel lymph node (s)’’.
All SLNs underwent frozen section examination. Negative
nodes were further subjected to routine H and E stained
permanent sections. Complete ALND was performed in the
case of failure of SLN identiﬁcation and in patients with posi-
tive SLN. ALND was performed as a second procedure if the
SLN was negative on the frozen section but proved to contain
metastatic disease on parafﬁn section. After removal of the
SLN(s), attention was directed to the primary tumor and either
wide local excision or mastectomy was performed.Pathological examination of the sentinel and non-sentinel lymph
nodes
SLNs were bi-valved and intraoperative frozen section (F.S.)
examination was performed. Step sections at two levels were
taken; each section was 4 lm thick. Negative and inconclusive
cases were deferred for parafﬁn embedded permanent section
evaluation. The intraoperative frozen section report of posi-
tive, negative, or inconclusive was submitted to the operating
surgical team. Additional information of micro (<2 mm) or
macro (P2 mm) metastases were given for the positive cases.
The average time utilized for F.S. examination was 12 min.
Negative and inconclusive SLNs were ﬁxed using 10% forma-
lin and routinely processed. Serial step-sections at three levels
at 75 lm intervals were taken; each section was 3 lm thick.
The sections were stained routinely with Hemtoxylin and
Eosin (H and E) and slides were examined for metastases.
Immunohistochemical stains (IHC) were performed for suspi-
cious cases using monoclonal antibody for cytokeratin AE1/3.
Otherwise, IHC was not routinely done.
Patients with positive SLN on intraoperative or permanent
section pathologic evaluation underwent synchronous or com-
pletion of ALND respectively. The lymph nodes were rou-
tinely processed and a single section, 3 lm thick, was taken
from each node. Slides were examined by two pathologists
before a report is issued.Analysis
Multiple variables were tested as possible predictors of non-
SLN metastasis. These included patient characteristics: tumor
location and method of breast cancer diagnosis (clinically or
mammographically detected), tumor characteristics: size, his-
tology, grade, estrogen and progesterone receptor and Her 2-
neu status, and lymphovascular invasion, and SLN character-
istics: number of positive SLNs, size of metastasis in the SLN
(micrometastasis from 0.2 to 2 mm, and macrometastasis
P2 mm), and presence of capsular invasion.
Statistical analysis was performed using SPSS statistical
software in addition to Chi2 and Fisher’s exact tests whenever
appropriate. A P value 6 0.05 was considered statistically
signiﬁcant.Results
The current study included 80 female patients having early
stage invasive breast cancer (T1, T2, N0 and M0) who under-
went SLNB procedure. Table 1 shows the clinicopathological
data of the patients.
The mean age at diagnosis was 46.6 years. Forty patients
(50%) had left breast cancer, 39 (48%) had right breast cancer,
and one patient had bilateral disease. The tumor was located in
the upper outer quadrant in the majority of cases (47 patients,
59%). Seventy two (91%) of patients presented clinically with
a breast lump and the remainder had mammographically de-
tected lesions. Seventy patients (87.5%) underwent wide local
excision of the primary tumor, and 10 patients (12.5%) under-
went mastectomy.
Table 1 The clinicopathological data of the patients with
breast cancer.
Patients data (n= 80) No. (%)
Age (years)
Mean
Range
46.6 ± 9.4
26–68
Clinical presentation
Breast lump
Mammographically detected
72 (91%)
8 (9%)
Side
Right breast
Left breast
Bilateral
39 (48%)
40 (50%)
1 (2%)
Operation
Wide local excision
Mastectomy
70 (87.5%)
10 (12.5%)
Tumor characteristics
Site
UOQ
UIQ
LIQ
LOQ
Central
47 (59%)
12 (15%)
10 (12%)
8 (10%)
3 (4%)
Size (cm)
Mean
Range
2.2 ± 1.2
0.8–11
Histology
IDC
ILC
Medullary
DCIS with microinvasion
Mucinous
58 (72.5%)
8 (10%)
6 (7.5%)
5 (6%)
3 (4%)
Grade (n= 63)
I
II
III
15 (24%)
35 (55%)
13 (21%)
Lymphovascular invasion
Positive
Negative
25 (31%)
55 (69%)
ER/PR status
Positive
Negative
Not available
64 (80%)
15 (18.8%)
1 (1.2%)
Her 2-neu status
Positive
Negative
Indeterminate
Not available
6 (8%)
65 (81%)
5 (6%)
4 (5%)
SLN characteristics
No. of SLNs removed
Mean
Range
2.7 ± 1.8
1–8
Size of largest SLN (cm)
Mean
Range
1.7 ± 0.7
0.6–3.5
No. of positive SLNs
Mean
Range
1.5 ± 0.9
1–6
Table 1 Continued.
Patients data (n= 80) No. (%)
Capsular invasion of positive SLN (n= 24)
Positive
Negative
12 (50%)
12 (50%)
Size of metastasis (n= 24)
0.2 mm
P 2 mm
4 (17%)
20 (83%)
UOQ: upper outer quadrant. UIQ: upper inner quadrent. LIQ:
lower inner quadrent.
LOQ: lower outer quadrent. IDC: invasive duct carcinoma. ILC:
invasive lobular carcinoma.
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noma (IDC); mostly grade II (55%), 8 patients (10%) had
Inﬁltrating Lobular Carcinoma (ILC), 6 (7.5%) medullary
carcinoma, 5 (6%) Ductal Carcinoma In Situ (DCIS) with
microinvasion, and 3 (4%) mucinous carcinoma. The median
tumor size was 2 cm.
Twenty ﬁve patients (31%) showed evidence of lymphovas-
cular invasion in the area of the primary tumor. Estrogen and
progesterone receptors were positive in 64 patients (80%); Her
2-neu was overexpressed in 6 patients (8%).
The SLNB was performed using a combined technique in
63 patients (79%), blue dye only in 14 (17%) or radiocolloid
only in 3 patients (4%). The SLN identiﬁcation rate was
96.2% (77 out of 80 patients). The SLN was positive in 24 pa-
tients (31%), and half of these showed evidence of capsular
invasion. Eighteen positive SLN (75%) were diagnosed by fro-
zen section and 6 (25%) were negative on frozen section but
found to harbor metastatic disease on parafﬁn section. The
median number of SLNs removed was 2, and the median num-
ber of positive SLNs was one. Four patients (17%) had micro-
metastasis, while 20 (83%) had macrometastasis in the SLN.
ALND was performed in 27 patients, 24 patients having
positive SLN and 3 patients in whom the SLN could not be
identiﬁed. The non-SLNs were positive in 12 out of 27 patients
(44%). If we excluded the 3 patients in whom ALND was per-
formed due to failure of identiﬁcation of the SLN (and in
whom also the ALND revealed negative non-SLNs), the inci-
dence of non-SLN metastasis associated with positive SLN will
be 50% (12 out of 24 patients).
The median number of non-SLNs removed by ALND was
20. The number of positive non-SLNs ranged from 1 (in 66%
of patients) to 7.
Lymphovascular invasion was found to be the only factor
associated signiﬁcantly with non-SLN metastases. All of the
12 patients with non-SLN metastasis had lymphovascular
invasion in the area of the primary tumor. On the other hand,
15 patients had negative non-SLNs, and nine of them had no
lymphovascular invasion. This association was found to be of
high statistical signiﬁcance (P 0.001).
Other clinicopathological variables were not found to be
predictors of statistical signiﬁcance. However, two trends were
observed: the ﬁrst is that the majority of patients having
capsular invasion of the SLN (8 out of 12 patients, 67%)
had non-SLN metastasis, and the second is that the patients
having more than one SLN metastasis were more likely to have
non-SLN metastasis (4 out of 5, 80%) (Table 2).
Table 2 Pathological variables predicting NSLN metastasis in breast cancer patients with positive SLN.
Pathological variable NSLN +ve NSLN ve P value
Frequency % Frequency %
Lymphovascular invasion
+ve 12 100 6 40.0 0.001
ve 0 0 9 60.0
Capsular invasion of +ve SLN
+ve 8 66.7 4 40.0 0.391
ve 4 33.3 6 60.0
Number of positive SLNs
1 8 47.1 4 80.0 0.323
>1 9 52.9 1 20.0
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Several investigators have examined the histopathological
variables of the primary tumor and the SLN metastasis that
can inﬂuence the risk of additional disease in the non-SLNs
(Table 3). This present extensive research was needed to an-
swer important questions – do all patients with positive SLNs
require ALND?, and if not, what is the selected subgroup of
SLN-positive patients in whom completion of ALND may
not be necessary?
The rationale for initiating these studies was based on two
important observations; the ﬁrst one is that in 40–70% of early
breast cancer patients the SLN is the only involved axillary
lymph node [1,16,29], which means that approximately half
of patients having positive SLN are undergoing ALND unnec-
essarily. The second observation was the low incidence of
regional failure in patients with SLN metastasis who did not
undergo ALND, either because of the associated serious
comorbidity that precluded ALND or because the patient re-
fused the procedure. In a study by Naik et al. [30], at a median
follow up of 31 months, the axillary recurrence was infrequent
both in SLN-positive patients who had completion ALND and
those who did not, 0.35% and 1.4% respectively. They com-
mented that this small difference, while statistically signiﬁcant,
may lack clinical signiﬁcance. Moreover, at a median follow up
of 28–32 months, Guenther et al. [31], Fant et al. [32], and
Jeruss et al. [33] found no axillary recurrences among SLN-po-
sitive patients who did not undergo ALND, and suggested that
patients with SLN metastasis are ideal candidates for trials
evaluating the necessity of ALND. Similarly, in a study by
Takei et al. [10], the relapse-free survival of patients with posi-
tive SLN treated with SLNB alone was almost identical to that
of patients with negative SLN treated with SLNB alone. These
results suggest that there is a subset of low risk, SLN-positive
patients in whom ALND might not be needed [30].
Advocates of ALND after positive SLN have stated that
the clinical and prognostic signiﬁcance of a precise count of
tumor-involved nodes justiﬁes the morbidity and cost of the
procedure, since the disease severity is directly related to
the number of positive nodes [34,35]. They also argued that
axillary dissection provides locoregional control and, there-
fore, the potential for improved overall survival [36]. Oppo-
nents argued that patients with SLN metastasis will receive
systemic therapy, regardless of any additional nodal metasta-
sis, and therefore any residual disease does not inﬂuencechoice of therapy and may itself be eradicated by the systemic
therapy. The current pattern of adjuvant therapy have re-
duced greatly the necessity for quantifying axillary disease,
and it is likely that breast radiation therapy (with opposing
tangents treating low axillary nodes), chemotherapy, and hor-
monal therapy will be effective in treating regional disease
[14]. Opponents also argued that a therapeutic beneﬁt of
ALND has never been proven conclusively, nor the effect
of locoregional failure on overall survival [31].
These debates have provoked the initiation of three large
randomized phase III studies: the American College Of Sur-
geons Oncology Group trial (ACOSOG Z0011) compares
overall survival, disease free survival, locoregional control,
and morbidity of ALND Vs no ALND after positive SLN
[37]; the After Mapping of the Axilla: Radiotherapy Or
Surgery (AMAROS) trial compares the efﬁcacy of axillary
radiotherapy with ALND in preventing axillary recurrence in
patients with positive SLNs [38]; and the International Breast
Cancer Study Group trial (IBCSG 23-01) randomizes patients
to ALND Vs no ALND after SLN micrometastasis to deter-
mine the prognostic signiﬁcance of SLN micrometastasis [39].
Among the clinicopathologic variables that would be useful
for predicting which early breast cancer patients are at higher
risk for additional non-SLN metastasis, size of the primary tu-
mor, size of the SLN metastasis and lymphovascular invasion
in the area of primary tumor were the most commonly ana-
lyzed (Table 3).
In the current study, Lymphovascular invasion was found
to be the only factor associated signiﬁcantly with non-SLN
metastases. Our results are comparable to those reported by
Travagli et al. [17] who studied the same clinicopathological
variables, though in a double number of patients, and found
that lymphatic invasion was the only factor that correlated
with metastasis to non-SLN.
In addition, in the current study, there was a tendency to-
ward higher incidence of non-SLN metastasis associated with
the increased number of positive SLNs and with capsular inva-
sion of SLN (though these did not reach the statistical signif-
icance, which could be attributed to the small number of
patients recruited). These two variables were also identiﬁed
by other authors (Table 2). Capsular invasion of the SLN is
a poor prognostic feature that usually occurs at the vascular
root of the lymph node hilum, with involvement of efferent
lymphatic vessels. Thus it represents tumor cells in-transit to
other sites [40]. Alkhatib et al. [41] found that a solitary
Table 3 Some of the studies reporting predictors of non-SLN metastasis in patients with positive SLNB, numbers represent the P
values, NS: not signiﬁcant.
Author No. of patients
with +ve SLN
% of non-SLN
metastasis (with
+ve SLN) (%)
Tumor size Lymphovascular
invasion
No. of
+ve SLNs
Size of SLN
metastasis
Capsular invasion
of positive SLN
Reynolds et al. [4] 60 46.5 0.0004 NS – 0.002
Chu et al. [11] 157 33.5 0.01 NS NS <0.0001 –
Turner et al. [19] 194 45 0.03 0.03 NS 0.01 0.0001
Viale et al. [20] 109 22 NS – – 0.02 –
Rahusen et al. [16] 93 49 NS NS 0.002 0.05 –
Abdessalam et al. [21] 100 40 NS 0.004 NS 0.01 0.001
Kamath et al. [1] 101 59.4 0.005 – – 0.001 –
Weiser et al. [22] 206 32 0.007 NS – 0.0002 –
Wong et al. [23] 389 37 <0 .001 – <0 .001 – –
Sachdev et al. [12] 55 60 0.0001 0.001 – 0.02 –
Travagli et al. [17] 50 30 NS 0.01 NS NS –
Van Zee et al. [14] 702 – 0.0006 0.003 0.0001 – –
Nos et al. [24] 263 24 0.01 NS NS <0 .001 NS
Van Iterson et al. [25] 135 34 0.03 – 0.01 0.006 NS
Stitzenberg et al. [13] 74 46 NS – NS NS 0.01
Saidi et al. [26] 34 32 0.04 0.03 – NS 0.001
Fournier et al. [27] 42 36 NS NS – 0.03 –
Fleming et al. [28] 54 48 NS NS – 0.02 0.01
Barranger et al. [29] 81 26.8 0.006 .006 0.04 0.01
Current study 24 50 NS 0.003 NS NS NS
28 H. Eldweny et al.positive SLN (without extracapsular extension) accompanied
by at least one negative SLN is associated with 3% risk of a
positive non-SLN.
The other two predictors of non-SLN metastasis that were
reported by most of the literature are the size of the primary
tumor and the size of lymph node metastasis. However, some
studies, including the current one, did not reach to the same
conclusion (Table 2). Noteworthy is the prognostic signiﬁcance
and the clinical implications of SLN micrometastasis which is
still a matter of debate and extensive research. While some
studies have concluded that patients with or without microme-
tastasis had no signiﬁcant prognostic differences [42,43], other
studies have shown that patients with micrometastasis have
higher recurrence rate and lower overall survival than patients
without lymph node metastasis [44,45]. Reynolds et al. [4], and
Chu et al. [11], found that the increasing size of the primary tu-
mor and increasing size of lymph node metastasis were associ-
ated with non-SLN involvement. On the other hand, one of the
most commonly utilized nomograms for predicting non-SLN
metastasis; the Memorial Sloan Kettering Cancer Center
(MSKCC) nomogram; [14] did not include the size of lymph
node metastasis as a predictive parameter. The authors of this
nomogram found difﬁculty in assessing the size of lymph node
metastasis because of the difference in the pattern of distribu-
tion of malignant cells within the node, some nodes may have
scattered single cells or multiple small clusters of cells, the size
of which cannot be measured. They commented that the vol-
ume of lymph node metastasis is a more accurate estimate,
but, according to their view, this is time consuming and some-
what impractical.
Several nomograms have been developed by different insti-
tutions to predict the probability of non-SLN metastasis. The
ﬁrst nomogram was developed by the MSKCC [14] and in-
cludes tumor size, grade, number of positive and negativeSLNs, method of detection of the SLN, estrogen receptor sta-
tus, lymphovascular invasion, and tumor multifocality. The
Tenon hospital nomogram [29] included tumor size, size of
SLN metastasis, and proportion of involved SLNs among all
removed SLNs. The Cambridge University nomogram [46]
uses grade, Overall Metastatic tumor Size (OMS, the largest
detected size of SLN metastasis), and the proportion of in-
volved SLNs among all removed SLNs. The ﬁnal nomogram,
the Stanford University nomogram [47], uses tumor size, status
of lymphovascular invasion, and the largest size of SLN metas-
tasis. The predictive accuracy of these nomograms has been
validated but the ﬁrst one is the most widely used [15]. How-
ever, it is limited by its complexity and inability to account
for the size of nodal metastasis [29,47].
The number of patients recruited to the current study is
small, which might have affected the results; however, this is
a pilot study that included all early breast cancer patients
who presented to a tertiary care referral center and who under-
went SLNB. Patient accrual is continuing to aim at more re-
ﬁned elucidation of the results. Another potential weakness
in the current study is the absence of the exact incidence of
SLN micrometastasis, because IHC was not routinely per-
formed. There might be undetected micrometastasis in some
of the negative SLNs, which might have correlated with nega-
tive non-SLNs. The reported occult metastasis detection rate is
in the range of 9–33% [48]. However, IHC is currently not a
part of the routine assessment of the SLN, but it is performed
for suspicious ﬁndings on H and E stains [15,49,50].
In conclusion, in the current pilot study, 50% of patients
with SLN metastasis had negative completion ALND and
the lymphovascular invasion in the area of the primary tumor
was found to be signiﬁcantly related to the non-SLN metasta-
sis. In addition, there was a tendency toward higher incidence
of non-SLN metastasis associated with the capsular invasion
Predictors of non-sentinel lymph node metastasis in breast cancer patients 29and number of positive SLNs, though this did not reach the
statistical signiﬁcance, which could be attributed to the small
number of patients recruited. Further evaluation of the predic-
tors of nonsentinel lymph node metastasis on a larger number
of patients is required. The validation of these predictors in
prospective studies may enable approximately half of early
stage breast cancer patients with positive SLN to be staged
with SLNB alone while avoiding the morbidity of unnecessary
ALND. Until the results of the large randomized studies com-
paring overall survival, disease free survival, locoregional con-
trol, and morbidity of ALND Vs no ALND after positive SLN
are available, the current recommendation is to proceed with
completion ALND in patients with SLN metastasis.
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